InvestorsHub Logo
Followers 0
Posts 75440
Boards Moderated 6
Alias Born 05/24/2005

Re: None

Thursday, 11/12/2015 10:35:45 PM

Thursday, November 12, 2015 10:35:45 PM

Post# of 1222
$$3-5 He continued, "We are very encouraged by the anatomical and histological data from our esophageal implant study. Based on these data, we believe that our second generation implant possesses all the necessary cues to elicit full regeneration of the esophagus. Importantly, our esophageal implant addresses a very significant need as a potentially life-saving treatment for patients with esophageal cancer. Each year in the U.S. approximately 17,000 new cases of esophageal cancer are diagnosed, and more than 4,000 are addressed by surgery. Our results underscore the value and potential of our platform technology to treat these patients and pave the way for further studies and our regulatory pathway for human clinical trials."






--MONEYMADE
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HRGN News